ZIM
KRYS icon

Zacks Investment Management’s Krystal Biotech KRYS Stock Holding History

Zacks Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,919
Closed -$4.63M – 779
2026
Q1 		$4.63M Buy
+17,919
New +$4.77M 0.04% 236
2025
Q1 		– Sell
-9,078
Closed -$1.42M – 711
2024
Q4 		$1.42M Sell
9,078
-369
-4% -$65.5K 0.01% 375
2024
Q3 		$1.72M Buy
9,447
+504
+6% +$97.2K 0.01% 359
2024
Q2 		$1.64M Buy
8,943
+914
+11% +$153K 0.02% 315
2024
Q1 		$1.43M Buy
+8,029
New +$1.12M 0.02% 361

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Zacks Investment Management's KRYS Position: Q2 2026 in Review

Zacks Investment Management sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 17,919 shares — an estimated $4.63M sold.

Zacks Investment Management first reported a position in KRYS in Q1 2024 and held it in 5 quarters. The position peaked at $4.63M in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Zacks Investment Management reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Zacks Investment Management sold 17,919 Krystal Biotech shares in Q2 2026, an estimated $4.63M.
  • Zacks Investment Management first reported a position in Krystal Biotech in Q1 2024 and held it in 5 quarters.
  • Zacks Investment Management's Krystal Biotech position peaked at $4.63M in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.